A Study Of PF-06263507 In Patients With Advanced Solid Tumors
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Lung Cancer, Ovarian Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/11/2019 |
| Start Date: | August 8, 2013 |
| End Date: | June 29, 2015 |
A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.
Inclusion Criteria:
- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for which no standard therapy is available.
- Performance Status of 0 or 1.
- Adequate bone marrow, kidney, liver, and heart function.
Exclusion Criteria:
- Brain metastases requiring steroids.
- Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
- Active bacterial, fungal or viral infection.
We found this trial at
4
sites
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials